Navigating Second-Line Treatments in 2026 CSU Guidelines, With Adam Friedman, MD

The 2026 international guidelines for chronic spontaneous urticaria (CSU) formalize 3 second-line treatment options: remibrutinib (Rhapsido), omalizumab (Xolair), and dupilumab (Dupixent).

Adam Friedman, MD, FAAD, professor and chair of dermatology, residency program director, Department of Dermatology, George Washington University School of Medicine and Health Sciences, discussed the update at the 2026 Dermatology Education Foundation (DEF) DERM2026 conference in Las Vegas. Click here to listen to the news.